General Information of the Drug (ID: M6APDG04336)
Name
CAR-T cells targeting CD133
Status
Preclinical
TTD Drug ID
D04JSI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Prominin-1 (PROM1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Prominin-1 (PROM1) is a therapeutic target for CAR-T cells targeting CD133. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CAR-T cells targeting CD133 through regulating the expression of Prominin-1 (PROM1). [1], [2]
References
Ref 1 The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2. J BUON. 2021 Mar-Apr;26(2):444-449.
Ref 2 Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59.